$14,82
+$0,00(0,00 %)
*Data last updated: 2026-04-29 09:20 (UTC+8)
As of 2026-04-29 09:20, Viatris Inc (VTRS) is priced at $14,82, with a total market cap of $17,25B, a P/E ratio of -4,14, and a dividend yield of 3,23 %. Today, the stock price fluctuated between $14,60 and $15,02. The current price is 1,50 % above the day's low and 1,33 % below the day's high, with a trading volume of 8,77M. Over the past 52 weeks, VTRS has traded between $14,60 to $15,02, and the current price is -1,33 % away from the 52-week high.
VTRS Key Stats
Yesterday's Close$14,81
Market Cap$17,25B
Volumen8,77M
P/E Ratio-4,14
Dividend Yield (TTM)3,23 %
Dividend Amount$0,12
Diluted EPS (TTM)3,05
Net Income (FY)-$3,51B
Revenue (FY)$14,29B
Earnings Date2026-05-07
EPS Estimate0,52
Revenue Estimate$3,35B
Shares Outstanding1,16B
Beta (1Y)0.822
Ex-Dividend Date2026-03-09
Dividend Payment Date2026-03-18
About VTRS
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CEOScott Andrew Smith
HeadquartersCanonsburg,PA,US
Official Websitehttps://www.viatris.com
Employees (FY)30,00K
Average Revenue (1Y)$476,66K
Net Income per Employee-$117,16K
Viatris Inc (VTRS) FAQ
What's the stock price of Viatris Inc (VTRS) today?
x
Viatris Inc (VTRS) is currently trading at $14,82, with a 24h change of 0,00 %. The 52-week trading range is $14,60–$15,02.
What are the 52-week high and low prices for Viatris Inc (VTRS)?
x
What is the price-to-earnings (P/E) ratio of Viatris Inc (VTRS)? What does it indicate?
x
What is the market cap of Viatris Inc (VTRS)?
x
What is the most recent quarterly earnings per share (EPS) for Viatris Inc (VTRS)?
x
Should you buy or sell Viatris Inc (VTRS) now?
x
What factors can affect the stock price of Viatris Inc (VTRS)?
x
How to buy Viatris Inc (VTRS) stock?
x
Risk Warning
The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.
Disclaimer
The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.
